BioCentury | Jul 18, 2016
Company News

Serendex, Savara deal

...Savara acquired fellow pulmonary company Serendex in a stock deal. Savara will gain Molgradex , a...
...Denmark) granted Serendex exclusive, worldwide rights to develop and commercialize Factor VIIa for pulmonary administration. Serendex...
...approval of Molgradex and Factor VIIa in Europe and Japan (see BioCentury, Feb. 16, 2015). Serendex Pharmaceuticals A/S...
BioCentury | Feb 16, 2015
Company News

CMC Biologics A/S, Serendex deal

...CMC granted Serendex exclusive, worldwide rights to develop and commercialize Factor VIIa for pulmonary administration. Serendex...
...next year. The companies declined to disclose financial details. CMC Biologics A/S , Copenhagen, Denmark Serendex Pharmaceuticals A/S...
Items per page:
1 - 2 of 2
BioCentury | Jul 18, 2016
Company News

Serendex, Savara deal

...Savara acquired fellow pulmonary company Serendex in a stock deal. Savara will gain Molgradex , a...
...Denmark) granted Serendex exclusive, worldwide rights to develop and commercialize Factor VIIa for pulmonary administration. Serendex...
...approval of Molgradex and Factor VIIa in Europe and Japan (see BioCentury, Feb. 16, 2015). Serendex Pharmaceuticals A/S...
BioCentury | Feb 16, 2015
Company News

CMC Biologics A/S, Serendex deal

...CMC granted Serendex exclusive, worldwide rights to develop and commercialize Factor VIIa for pulmonary administration. Serendex...
...next year. The companies declined to disclose financial details. CMC Biologics A/S , Copenhagen, Denmark Serendex Pharmaceuticals A/S...
Items per page:
1 - 2 of 2